Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

Harrison, Stephen A., Bashir, Mustafa, Moussa, Sam E. · Hepatology Communications · 2021